Positron emission tomography in the management of lung cancer

Annals of Thoracic Medicine

Volumn 2, Issue 2, 2007, Pages 69-76

  Dabbagh Kakhki, Vahid ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Lung cancer; PET computed tomography; Positron emission tomography (PET); Therapy response; Tumor staging

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; PLATINUM DERIVATIVE;

CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG NODULE; MEDIASTINUM LYMPH NODE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TISSUE METABOLISM; TREATMENT PLANNING; TREATMENT RESPONSE; WHOLE BODY SCINTISCANNING;

EID: 34249307802     PISSN: 18171737     EISSN: None     Source Type: Journal    
DOI: 10.4103/1817-1737.32235     Document Type: Review

References (73)

1. Vansteenkiste JF, Stroobants SG. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur Respir J 2001;17:802-20.
2. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S.
3. Fanti S, Franchi R, Battista G, Monetti N, Canini R. PET and PETCT. State of the art and future prospects. Radiol Med (Torino) 2005;110:1-15.
4. Czernin J. Schelbert H. PET/CT imaging: Facts, opinions, hopes and questions. J Nucl Med 2004;45:1S.
5. Sureshbabu W, Mawlawi O. PET/CT imaging artifacts. J Nucl Med Technol 2005;33:156-61.
6. Barra V, Boire JV. A general framework for the fusion of anatomical and functional medical images. Neuroimage 2001;13:410-24.
7. Tsukamoto E, Ochi S. PET/CT today: System and its impact on cancer diagnosis. Ann Nucl Med 2006;20:255-67.
8. Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDG PET uptake-the Role of PET/CT. Eur Radiol 2006;16:1054-65.
9. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PETCT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics 2004;24:1411-31.
10. Minotti AJ, Shah L, Keller K. Positron emission tomography/computed tomography fusion imaging in brown adipose tissue. Clin Nucl Med 2004;29:5-11.
11. Yeung HW, Grewal RK, Gonen M, Schoder H, Larson SM. Patterns of (18)F-FDG uptake in adipose tissue and muscle: A potential source of false-positives for PET. J Nucl Med 2003;44:1789-96.
12. th ed. Lippincott Williams and Wilkins: Philadelphia; 2003. p. 987-1014.
13. Sarinas PS, Chitkara RK, Buadu EO, Gould MK, Kuschner WG, Segall GM. Usefulness of positron emission tomography imaging in the management of lung cancer. Curr Opin Pulm Med 1999;5:201-7.
14. Sarinas PS, Chitkara RK. PET and SPECT in the management of lung cancer. Curr Opin Pulm Med 2002;8:257-64.
15. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasuk K, Unok. Visual and semiquantitative analyses for F-18fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size. Ann Thorac Surg 2005;79:984-9.
16. Herder GJ, Van Tinteren H, Golding RP, Kostense PJ, Comans EF, Smit EF, et al. Clinical prediction model to characterize pulmonary nodules: Validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest 2005;128:2490-6.
17. Hashimoto Y, Tsujikawa T, Kondo C, Maki M, Momose M, Nagai A, et al. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med 2006;47:426-31.
18. Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 2006;82:1016-20.
19. Pitman AG, Hicks RJ, Kalff V, Binns DS, Ware RE, McKenzie AF, et al. Positron emission tomography in pulmonary masses where tissue diagnosis is unhelpful or not possible. Med J Aust 2001;175:303-7.
20. Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003;362:593-7.
21. Bastarrika G, Garcia-Velloso MJ, Lozano MD, Montes U, Torre W, Spiteri N, et al. Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med 2005;171:1378-83.
22. Vansteenkiste J, Dooms C. Positron emission tomography in non-small cell lung cancer. Curr Opin Oncol 2007;19:78-83.
23. Mountain CF. The international system for staging lung cancer. Semin Surg Oncol 2000;18:106-15.
24. Bruzzi JF, Munden RF. PET/CT imaging of lung cancer. J Thorac Imaging 2006;21:123-36.
25. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-61.
26. Herder GJ, Kramer H, Hoekstra OS, Smit EF, Pruim J, van Tinteren H, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: A Dutch cooperative randomized study. J Clin Oncol 2006;24:1800-6.
27. Lardinois D, Weder W, Roudas M, von schulthess GK, Tutic M, Moch H, et al. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol 2005;23:6846-53.
28. Sachs S, Bilfinger TV. The impact of positron emission tomography on clinical decision making in a university-based multidisciplinary lung cancer practice. Chest 2005;128:698-703.
29. Devaraj A, Cook GJ, Hansell DM. PET/CT in non-small cell lung cancer staging-promises and problems. Clin Radiol 2007;62:97-108.
30. Lavrenov K, Partridge M, Cook G, Brada M. Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. Radiother Oncol 2005;77:1-4.
31. Gupta NC, Rogers JS, Graeber GM, Graeber GM, Gregory JL, Waheed U, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 2002;122:1918-24.
32. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-44.
33. Higashi K, Ito K, Hiramatsu Y, Ishikawa T, Sakuma T, Mastunari I, et al. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J Nucl Med 2005;46:267-73.
34. Nomori H, Watanabe K, Ohtsuka T, Naruke T Suemasa K, Kobayashi T, et al. Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness or both, in clinical T1 N0 M0 lung adenocarcinoma. J Thorac Cardiovasc Surg 2004;128:396-401.
35. Jeong HJ, Min JJ, Park JM, Chung JK, Kim BT, Jeong JM, et al. Determination of the prognostic value of [(18)F]fluorodeoxyglu cose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002;23:865-70.
36. Dunagan D, Chin R Jr, McCain T, Case L, Harkness B, Oaks T, et al. Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer. Chest 2001;119:333-9.
37. Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43:39-45.
38. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7.
39. Rajadhyaksha CD, Bader DA, Barbaras L, Parker JA. 18FDG-PETCT in lung cancer. An interactive web based image atlas. Joint Program Nucl Med. Available from: http://www.jpnm.org/.
40. Halpern BS, Schiepers C, Weber WA, Crawford TL, Fueger BJ, Phelps ME, et al. Presurgical staging of non-small cell lung cancer: Positron emission tomography, integrated positron emission tomography/CT and software image fusion. Chest 2005;128:2289-97.
41. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s-metaanalytic comparison of PET and CT. Radiology 1999;213:530-6.
42. Pozo-Rodriguez F, Martin de Nicolas JL, Sanchez-Nistal MA, Maldonado A, Garcia de Barajas S, Calero-Garcia R, et al. Accuracy of helical computed tomography and [18F]fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol 2005;23:8348-56.
43. Gupta NC, Tamim WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 2001;120:521-7.
44. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: A meta-analysis. Ann Intern Med 2003;139:879-92.
45. Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F; American College of Chest Physicians. The noninvasive staging of non-small cell lung cancer: The guidelines. Chest 2003;123:147S-56S.
46. Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterback KW, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: Priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000;27:1598-609.
47. de Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS. The size of mediastinal lymph nodes and its relation with metastatic involvement: A meta-analysis. Eur J Cardiothorac Surg 2006;29:26-9.
48. Hoekstra CJ, Stroobants SG, Hoekstra OS, Vansteenkiste J, Biesma B, Schramel FJ, et al. The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer 2003;39:151-7.
49. MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: Implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287-93.
50. Eschmann SM, Friedel G, Paulsen F, Budach W, Harer-Mouline C, Dohmen BM, et al. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 2002;29:804-8.
51. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244-7.
52. Kumar R, Xiu Y, Yu JQ, Takalkar A, El-Haddad G, Potenta S, et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 2004;45:2058-62.
53. Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol 2000;175:245-9.
54. Schaffler GJ, Wolf G, Schoellnast H, Groell R, Maier A, Smolle-Juttner FM, et al. Non-small cell lung cancer: Evaluation of pleural abnormalities on CT scans with 18F FDG PET. Radiology 2004;231:858-65.
55. Lewis P, Griffin S, Marsden P, Gee T, Nunan T, Malsey M, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344:1265-6.
56. Wolfgang A, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-7.
57. Choi NC, Fischman AJ, Niemierko A, Ryu JS, Lynch T, Wain J, et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:1024-35.
58. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-7.
59. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002;35:179-87.
60. Hicks RJ, Kal V, MacManus MP, Ware RE, McKenzie AF, Matthews JP, et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med 2001;42:1605-13.
61. Hebert ME, Lowe VJ, Hoffman JM, Patz EF, Anscher MS. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 1996;19:416-21.
62. Keidar Z, Haim N, Guralnik L, Wollner M, Bar-Shalom R, Ben-Nun A, et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: Diagnostic value and impact on patient management. J Nucl Med 2004;45:1640-6.
63. Koenig TR, Munden RF, Erasmus JJ, Sabloff BS, Gladish GW, Komaki R, et al. Radiation injury of the lung after three-dimensional conformal radiation therapy. AJR Am J Roentgenol 2002;178:1383-8.
64. Hicks RJ, Mac Manus MP, Matthews JP, Hogg A, Binns D, Rischin D, et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: Inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004;60:412-8.
65. Senan S, De Ruysscher D, Giraud P, Mirimanoff R, Budach V; Radiotherapy Group of European Organization for Research and Treatment of Cancer. Literature-based recommendations for treatment planning and execution for high-precision radiotherapy in lung cancer. Radiother Oncol 2004;71:139-46.
66. De Ruysscher D, Wanders S, van Haren E, Hochstenbag M, Geeraedts W, Utama I, et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non small cell lung cancer: A prospective clinical study. Int J Radiat Oncol Biol Phys 2005;62:988-94.
67. van Der Wel A, Nijsten S, Hochstenbag M, Lamers R, Boersma L, Wanders R, et al. Increased therapeutic ratio by 18FDG-PET-CT planning in patients with clinical CT stage N2-N3 M0 non-small-cell lung cancer: A modeling study. Int J Radiat Oncol Biol Phys 2005;61:649-55.
68. Senan S, De Ruysscher D. Critical review of PET-CT for radiotherapy planning in lung cancer. Crit Rev Oncol Hematol 2005;56:345-51.
69. Ashamalla H, Rafla S, Parikh K, Mokhtar B, Goswami G, Kambam S, et al. The contribution of integrated PET/ CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 2005;63:1016-23.
70. Gambhir SS, Shepherd JE, Shah BD, Hart E, Hoh CK, Valk PE, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113-25.
71. Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: A decision analysis. Ann Thorac Surg 1998;66:1876-85.
72. Alzahouri K, Lejeune C, Woronoff-Lemski MC, Arveux P, Gaillemin F. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective. Clin Radiol 2005;60:479-92.
73. Yap KK, Yap KS, Byrne AJ, Berlangieri SU, Poon A, Mitchell P, et al. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2005;32:1033-40.